Reuters logo
BRIEF-Intercept Pharma reports qtrly ‍revenue $41.3 mln vs $5.2 million​
November 1, 2017 / 11:48 AM / 24 days ago

BRIEF-Intercept Pharma reports qtrly ‍revenue $41.3 mln vs $5.2 million​

Nov 1 (Reuters) - Intercept Pharmaceuticals Inc

* Intercept Pharmaceuticals reports third quarter 2017 financial results and provides business update

* Intercept - ‍non-GAAP adjusted operating expenses for fiscal year ending Dec 31, 2017 will fall in middle of range of $380 million to $420 million​

* Intercept Pharmaceuticals - ‍interim analysis in flagship Phase 3 regenerate trial on track to report in H1 2019

* Intercept Pharmaceuticals Inc- to streamline operating expenses, decided to deprioritize interest-767 development program for foreseeable future​

* Intercept Pharmaceuticals Inc - qtrly ‍rev $41.3 million versus $5.2 million​

* Q3 earnings per share view $-3.38, revenue view $37.0 million -- Thomson Reuters I/B/E/S

* Intercept Pharmaceuticals inc qtrly net loss per common and potential common share basic and diluted $2.89‍​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below